Soligenix Inc. Advances in Rare Disease Therapeutics with HyBryte(TM) Platform

Soligenix Inc. (NASDAQ: SNGX) has recently been spotlighted for its advancements in the field of rare disease therapeutics, with a particular focus on conditions affecting the aging population. The company's HyBryte(TM) platform, designed to treat cutaneous T-cell lymphoma (CTCL), a rare skin cancer predominantly found in older adults, stands out as a beacon of hope for over 30 million Americans living with rare diseases, many of which lack FDA-approved treatments.

The significance of Soligenix's work cannot be overstated, as it addresses a critical gap in healthcare for rare diseases. The successful domestic manufacturing of HyBryte's active ingredient marks a pivotal step forward in the company's mission to provide innovative, U.S.-based therapies. This development is especially important given the challenges associated with treating rare diseases, which often include limited research funding and a lack of interest from larger pharmaceutical companies due to the small patient populations affected.

HyBryte(TM), also known as SGX301 or synthetic hypericin, represents a novel photodynamic therapy that utilizes safe visible light for the treatment of CTCL. With the completion of a second Phase 3 study, Soligenix is now poised to seek regulatory approvals for HyBryte(TM), aiming to make this treatment available worldwide. The potential commercialization of HyBryte(TM) could significantly improve the quality of life for patients suffering from this rare form of skin cancer.

Beyond CTCL, Soligenix is exploring the application of synthetic hypericin in treating psoriasis and developing other innovative therapies, including a first-in-class innate defense regulator technology for inflammatory diseases. The company's commitment to addressing unmet medical needs extends to its Public Health Solutions business segment, which focuses on vaccine development for diseases like ricin toxin, filoviruses, and COVID-19, supported by government grants and contracts. For more information on Soligenix's groundbreaking work in rare disease therapeutics, visit https://www.Soligenix.com. The company's progress in this field underscores the importance of continued investment and innovation in treatments for rare diseases, offering hope to millions of patients and their families.